The molecular concept of atheromatous plaques

© 2017 Bentham Science Publishers. Background: Recently, there are scientific attempts to discover new drugs in the biotechnology industry in order to treat various diseases including atherosclerosis. Objective: The main objective of the present review was to highlight the cellular, molecular biolog...

Full description

Saved in:
Bibliographic Details
Main Authors: Zar Chi Thent, Chiranjib Chakraborty, Pasuk Mahakkanukrauh, Nik Ritza Kosai Nik Mahmood, Reynu Rajan, Srijit Das
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85028991757&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/46473
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-46473
record_format dspace
spelling th-cmuir.6653943832-464732018-04-25T07:33:35Z The molecular concept of atheromatous plaques Zar Chi Thent Chiranjib Chakraborty Pasuk Mahakkanukrauh Nik Ritza Kosai Nik Mahmood Reynu Rajan Srijit Das Agricultural and Biological Sciences © 2017 Bentham Science Publishers. Background: Recently, there are scientific attempts to discover new drugs in the biotechnology industry in order to treat various diseases including atherosclerosis. Objective: The main objective of the present review was to highlight the cellular, molecular biology and inflammatory process related to the atheromatous plaques. Methods: A thorough literature search of Pubmed, Google and Scopus databases was done. Results: Atherosclerosis is considered to be a leading cause of death throughout the world. Atherosclerosis involves oxidative damage to the cells with production of reactive oxygen species (ROS). Development of atheromatous plaques in the arterial wall is a common feature. Specific inflammatory markers pertaining to the arterial wall in atherosclerosis may be useful for both diagnosis and treatment. These include Nitric oxide (NO), cytokines, macrophage inhibiting factor (MIF), leucocytes and Pselectin. Modern therapeutic paradigms involving endothelial progenitor cells therapy, angiotensin II type-2 (AT 2 R) and ATP-activated purinergic receptor therapy are notable to mention. Conclusion: Future drugs may be designed aiming three signalling mechanisms of AT 2 R which are (a) activation of protein phosphatases resulting in protein dephosphorylation (b) activation of bradykinin/nitric oxide/cyclic guanosine 3',5'-monophosphate pathway by vasodilation and (c) stimulation of phospholipase A(2) and release of arachidonic acid. Drugs may also be designed to act on ATP-activated purinergic receptor channel type P2X7 molecules which acts on cardiovascular system. 2018-04-25T06:55:24Z 2018-04-25T06:55:24Z 2017-01-01 Journal 18735592 13894501 2-s2.0-85028991757 10.2174/1389450117666160502151600 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85028991757&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/46473
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Agricultural and Biological Sciences
spellingShingle Agricultural and Biological Sciences
Zar Chi Thent
Chiranjib Chakraborty
Pasuk Mahakkanukrauh
Nik Ritza Kosai Nik Mahmood
Reynu Rajan
Srijit Das
The molecular concept of atheromatous plaques
description © 2017 Bentham Science Publishers. Background: Recently, there are scientific attempts to discover new drugs in the biotechnology industry in order to treat various diseases including atherosclerosis. Objective: The main objective of the present review was to highlight the cellular, molecular biology and inflammatory process related to the atheromatous plaques. Methods: A thorough literature search of Pubmed, Google and Scopus databases was done. Results: Atherosclerosis is considered to be a leading cause of death throughout the world. Atherosclerosis involves oxidative damage to the cells with production of reactive oxygen species (ROS). Development of atheromatous plaques in the arterial wall is a common feature. Specific inflammatory markers pertaining to the arterial wall in atherosclerosis may be useful for both diagnosis and treatment. These include Nitric oxide (NO), cytokines, macrophage inhibiting factor (MIF), leucocytes and Pselectin. Modern therapeutic paradigms involving endothelial progenitor cells therapy, angiotensin II type-2 (AT 2 R) and ATP-activated purinergic receptor therapy are notable to mention. Conclusion: Future drugs may be designed aiming three signalling mechanisms of AT 2 R which are (a) activation of protein phosphatases resulting in protein dephosphorylation (b) activation of bradykinin/nitric oxide/cyclic guanosine 3',5'-monophosphate pathway by vasodilation and (c) stimulation of phospholipase A(2) and release of arachidonic acid. Drugs may also be designed to act on ATP-activated purinergic receptor channel type P2X7 molecules which acts on cardiovascular system.
format Journal
author Zar Chi Thent
Chiranjib Chakraborty
Pasuk Mahakkanukrauh
Nik Ritza Kosai Nik Mahmood
Reynu Rajan
Srijit Das
author_facet Zar Chi Thent
Chiranjib Chakraborty
Pasuk Mahakkanukrauh
Nik Ritza Kosai Nik Mahmood
Reynu Rajan
Srijit Das
author_sort Zar Chi Thent
title The molecular concept of atheromatous plaques
title_short The molecular concept of atheromatous plaques
title_full The molecular concept of atheromatous plaques
title_fullStr The molecular concept of atheromatous plaques
title_full_unstemmed The molecular concept of atheromatous plaques
title_sort molecular concept of atheromatous plaques
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85028991757&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/46473
_version_ 1681422881170391040